Galapagos Subsidiary BioFocus Collaborate with Senexis
News Dec 02, 2005
Senexis Limited and Galapagos NV have announced that they have expanded their collaboration to optimise Senexis' inhibitors of amyloid-induced toxicity and neuroinflammation for the treatment of Alzheimer's disease.
Galapagos will receive research fees for the medicinal chemistry services provided to Senexis.
The collaboration aims to significantly advance Senexis' small molecule Alzheimer's programs towards the clinic and is unrelated to Galapagos' own Alzheimer's disease targets program.
"We are delighted to continue our successful collaboration with BioFocus," said David Scopes, Senexis' Chief Scientific Officer.
"We have now made significant progress with our small molecule programmes, so that our lead series now demonstrate similar potency to peptides when inhibiting amyloid-induced toxicity."
Onno van de Stolpe, Galapagos' CEO, commented, "We are pleased that BioFocus has been able to help advance Senexis' Alzheimer's program, and offering our medicinal chemistry expertise should further help to accelerate their development program."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018